Hjem › Brystkreft › Nevada › Reno
Kliniske studier for Brystkreft i Reno, NV
13 studier for Brystkreft søker deltakere på steder i og rundt Reno (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
RekruttererFase 3
- Cancer Care Specialists, Reno
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Renown Regional Medical Center, Reno
- Saint Mary's Regional Medical Center, Reno
- Carson Tahoe Regional Medical Center, Carson City · 25 mi unna
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
RekruttererFase 2
- Cancer Care Specialists, Reno
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RekruttererFase 3
- Renown Regional Medical Center ( Site 0041), Reno
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RekruttererFase 1/2
- Renown Regional Medical Center, Reno
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
RekruttererFase 3
- Research Site, Reno
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RekruttererFase 3
- Renown Health Medical Oncology, Reno
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
RekruttererObservasjonsstudie
- Cancer Care Specialist of Reno, Reno
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RekruttererFase 3
- Renown Regional Medical Center, Reno
- Saint Mary's Regional Medical Center, Reno
- Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee · 24 mi unna
- og 1 flere
E-Mindfulness Approaches for Living After Breast Cancer
RekruttererFase 3
- Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee · 24 mi unna
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
RekruttererFase 3
- Renown Regional Medical Centre, Reno
- Cancer Care Specialists, Reno
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
RekruttererFase 3
- Renown Regional Medical Center, Reno
- Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee · 24 mi unna
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
RekruttererFase 1
- Renown Regional Medical Center, Reno
Brystkreft-studier i andre byer
- New York City, NY134 studier
- Houston, TX126 studier
- Boston, MA111 studier
- Nashville, TN80 studier
- Los Angeles, CA72 studier
- Edison, NJ68 studier
- St. Louis, MO64 studier
- Durham, NC63 studier
- Queens, NY63 studier
- Chicago, IL58 studier
- Philadelphia, PA56 studier
- Dallas, TX55 studier
Andre studier i Reno
- Ikke-småcellet lungekreft16 studier
- Lungekreft9 studier
- Makuladegenerasjon8 studier
- Geografisk atrofi8 studier
- Eggstokkreft7 studier
- Kreft (alle typer)7 studier
- Kolorektal kreft5 studier
- Akut myelogen leukemi5 studier
- Metastatisk kreft5 studier
- Pankreaskreft5 studier
- Tykktarmskreft5 studier
- Endetarmskreft4 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.